Literature DB >> 2451691

IFN-mediated induction of MHC antigen expression on human keratinocytes and its influence on in vitro alloimmune responses.

D Niederwieser1, J Auböck, J Troppmair, M Herold, G Schuler, G Boeck, J Lotz, P Fritsch, C Huber.   

Abstract

The MHC Ag expression on the surface of keratinocytes is altered after treatment with IFN. IFN-gamma induces, as expected, a strong increase in class I MHC Ag expression as well as de novo expression of class II MHC Ag, whereas IFN-alpha 2 only slightly increases class I MHC Ag and does not induce keratinocytes to express class II MHC Ag. We used untreated and IFN-pretreated keratinocytes as stimulators and also as targets to study whether IFN-induced MHC Ag changes would alter the immunogenicity of keratinocytes in alloimmune responses. It was found that class II MHC Ag-carrying keratinocytes were unable to induce the proliferation of resting lymphocytes, but did stimulate T blasts. Untreated keratinocytes were virtually resistant to the lysis by classical CTL but became susceptible after exposure to IFN-gamma, but not IFN-alpha 2 at physiologic doses. These data demonstrate mechanisms by which the release of IFN-gamma might contribute to the development of disease such as the graft vs host disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2451691

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Interferon-alpha (IFN-alpha) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC).

Authors:  K J Palmer; M Harries; M E Gore; M K Collins
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

2.  Tumour necrosis factor enhances the interferon-gamma-induced class II MHC antigen expression on murine keratinocytes in vivo.

Authors:  K Nakamura; K Tamaki
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

3.  Alloantigen-specific T-cell anergy induced by human keratinocytes is abrogated upon loss of cell-cell contact.

Authors:  H G Otten; B Bor; C Ververs; L F Verdonck; M De Boer; G C De Gast
Journal:  Immunology       Date:  1996-06       Impact factor: 7.397

Review 4.  Keratinocytes: key immunocytes of the integument.

Authors:  B J Nickoloff; L A Turka
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

5.  Synthetic skin-permeable proteins enabling needleless immunization.

Authors:  Yongzhuo Huang; Yoon Shin Park; Cheol Moon; Allan E David; Hee Sun Chung; Victor C Yang
Journal:  Angew Chem Int Ed Engl       Date:  2010-04-01       Impact factor: 15.336

6.  Immunoelectron microscopic analysis of Ia antigen expression in rat skin during limb allograft rejection.

Authors:  M Mohtai; Y Sugioka; T Hotokebuchi; K Arai; A Hirana; K Wasano; N Kaibara
Journal:  Am J Pathol       Date:  1990-02       Impact factor: 4.307

7.  Enhanced serum levels of soluble HLA class I molecules are induced by treatment with recombinant interferon-gamma (IFN-gamma).

Authors:  W E Aulitzky; H Grosse-Wilde; U Westhoff; H Tilg; W Aulitzky; G Gastl; M Herold; C Huber
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

8.  IL-2, IL-3, and IFN-gamma differently affect in vivo frequencies of circulating precursors of cytotoxic T lymphocytes (CTL-P).

Authors:  F Hladik; K Kolbe; E U Irschick; M J Aman; G Gerken; L Färber; E Liehl; C Peschel; W E Aulitzky; C Huber
Journal:  Ann Hematol       Date:  1993-08       Impact factor: 3.673

9.  Lytic susceptibility of target cells to cytotoxic T cells is determined by their constitutive major histocompatibility complex class I antigen expression and cytokine-induced activation status.

Authors:  M Ritter; C Huber; J Auböck; H Pohl-Markl; J Troppmair; M Herold; A Gächter; W Nussbaumer; G Böck; D Nachbaur
Journal:  Immunology       Date:  1994-04       Impact factor: 7.397

10.  Specificity of T cells invading the skin during acute graft-vs.-host disease after semiallogeneic bone marrow transplantation.

Authors:  J Gaschet; B Mahé; N Milpied; M C Devilder; B Dréno; J D Bignon; F Davodeau; M M Hallet; M Bonneville; H Vié
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.